GeneReach Biotechnology Working Capital to Net Assets Ratio
GeneReach Biotechnology working capital to net assets ratio. GeneReach Biotechnology (4171) has a Working Capital to Net Assets ratio of 48.2% as of June 2026. Working capital of NT$280.30 Million (current assets of NT$479.21 Million minus current liabilities of NT$198.91 Million) is measured against net assets of NT$581.48 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check GeneReach Biotechnology tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of GeneReach Biotechnology (2017–2025)
Working capital to net assets ratio of GeneReach Biotechnology from 2017 to 2025. This chart shows how GeneReach Biotechnology's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of June 2026, the ratio stands at 48.2%, reflecting working capital of NT$280.30 Million against net assets of NT$581.48 Million TWD. See how many days can GeneReach Biotechnology fund operations to measure how many days the company can operate on defensive assets alone.
GeneReach Biotechnology Working Capital to Net Assets Ratio by Year (2017–2025)
GeneReach Biotechnology working capital to net assets ratio by year from 2017 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for GeneReach Biotechnology from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 4171 total assets.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 47.4% | NT$283.03 Million | NT$596.72 Million | NT$484.16 Million | NT$201.13 Million | ▼ -1.5 pp |
| 2024 | 49.0% | NT$355.14 Million | NT$725.49 Million | NT$594.67 Million | NT$239.53 Million | ▼ -0.5 pp |
| 2023 | 49.4% | NT$426.24 Million | NT$862.44 Million | NT$632.14 Million | NT$205.90 Million | ▼ -12.7 pp |
| 2022 | 62.1% | NT$684.99 Million | NT$1.10 Billion | NT$1.07 Billion | NT$385.09 Million | ▼ -20.8 pp |
| 2021 | 82.9% | NT$902.32 Million | NT$1.09 Billion | NT$1.18 Billion | NT$278.21 Million | ▲ +18.4 pp |
| 2020 | 64.5% | NT$553.50 Million | NT$857.76 Million | NT$798.64 Million | NT$245.14 Million | ▲ +11.9 pp |
| 2019 | 52.6% | NT$312.23 Million | NT$593.05 Million | NT$399.91 Million | NT$87.68 Million | ▲ +33.3 pp |
| 2018 | 19.4% | NT$60.31 Million | NT$311.15 Million | NT$432.70 Million | NT$372.39 Million | ▲ +42.0 pp |
| 2017 | -22.6% | NT$-56.73 Million | NT$250.63 Million | NT$282.67 Million | NT$339.40 Million | — |